Disease progression defined as per RECIST v1.1 and monitored throughout the study period. Progression Free Survival defined as time from study registration to disease progression or death from any cause.

Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, Abemaciclib and Encorafenib Plus Cetuximanb

PK: AUC of Gemcitabine when Administered with LY3214996

(and 11 more...)

272

All

18 Years and older (Adult, Older Adult)

NCT02857270

16419I8S-MC-JUAB2016-001907-21

September 29, 2016

December 15, 2021

December 15, 2021

August 5, 2016

August 5, 2019

Georgetown University Medical CenterWashington, District of Columbia, United States

Florida Cancer SpecialistsSarasota, Florida, United States

Massachusetts General HospitalBoston, Massachusetts, United States

(and 10 more...)

† Study has passed its completion date and status has not been verified in more than two years.